Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(−) breast cancer that had progressed during or after prior endocrine therapy

BACKGROUND: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–positive (HR(+)), human epidermal growth factor receptor 2–negative (HER2(−)) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovit...

Descripción completa

Detalles Bibliográficos
Autores principales: Musolino, Antonino, Campone, Mario, Neven, Patrick, Denduluri, Neelima, Barrios, Carlos H., Cortes, Javier, Blackwell, Kimberly, Soliman, Hatem, Kahan, Zsuzsanna, Bonnefoi, Hervé, Squires, Matthew, Zhang, Yong, Deudon, Stephanie, Shi, Michael M., André, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301372/
https://www.ncbi.nlm.nih.gov/pubmed/28183331
http://dx.doi.org/10.1186/s13058-017-0807-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301372/
https://www.ncbi.nlm.nih.gov/pubmed/28183331
http://dx.doi.org/10.1186/s13058-017-0807-8

Ejemplares similares